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Aim: Concurrent chemoradiotherapy (CCRT) is the current standard treatment for
inoperable stage III non-small cell lung cancer (NSCLC). We aimed to evaluate efficacy
and toxicity of CCRT with split dose of cisplatin (30 mg/m2) and vinorelbine (20 mg/
m2) during radiotherapy.
Methods: Some 97 consecutive patients with inoperable stage III NSCLC treated with
concurrent chemoradiotherapy with split-dose cisplatin-vinorelbine were
retrospectively analyzed. Cisplatin (30 mg/m/2) and vinorelbine (20 mg/m2) were
administered on days 1, 8, 22, and 29 during radiotherapy. Two cycles of consolidation
chemotherapy were given after CCRT.
Results: Details of the 97 consecutive unresectable stage III NSCLC patients treated
with CCRT and included into this study are as follws .Median age was 58 years old
(range 39-75) and 87 (89.7%) of the patients were men. ECOG performance score was
0-1 in 93 patients (95.9%). Squamous histology, most common histology, was
diagnosed in 46 patients (47.4%). Median follow-up time was 23.8 months. Median
progression-free survival (PFS) and median overall survival time (OS) were 10.3
months and 17.8 months, respectively. Objective response rate and clinical benefit rate
were 75.3% and 83.5%, respecively. Distant and local relapse rates were found as 57.1%
and 42.9 %. Hematological and non-hematlogical grade 3-4 toxicities were seen in 13
(13.4%) and 16 (16.5%) patients, respectively. Six (6.1%) patients died of toxicity.
Conclusions: This study suggested that split-dose cisplatin may offer fewer grade III,
IV toxicities without sacrificing efficacy. Similar to past studies, despite the high
response rate during CCRT, distant relapse is the major parameter that influences on
patient survival long term in NSCLC.
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